Q-omics provides the consensus-scored PPP2R2B profile across patient tissues and cancer cell-line models. PPP2R2B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PPP2R2B is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, PPP2R2B RNA expression shows 17,346 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where PPP2R2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP2R2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP2R2B survival associations across molecular data types. PPP2R2B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP2R2B RNA expression–survival associations across cancer types. High PPP2R2B expression shows unfavorable associations in KIRP and UVM, but favorable associations in BRCA, ACC, BLCA and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PPP2R2B RNA expression.
This table summarizes PPP2R2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PPP2R2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP2R2B shows lower tumor expression in KIRC, KICH, COAD, KIRP and THCA and higher tumor expression in HNSC. The KIRC box plot shows higher PPP2R2B RNA expression in normal versus tumor tissue (log2 FC = −1.279, t-test p < 0.001).
This table shows molecular features associated with PPP2R2B in patient tissues and cancer cell lines. In patient samples, PPP2R2B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP2R2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
